Iyengar Karthikeyan P, Jain Vijay Kumar, Ish Pranav
Trauma and Orthopaedic Surgeon, Southport and Ormskirk NHS Trust, Southport.
Department of Orthopaedics, Atal Bihari Vajpayee Institute of Medical Sciences, Dr Ram Manohar Lohia Hospital, New Delhi.
Monaldi Arch Chest Dis. 2020 Nov 30;90(4). doi: 10.4081/monaldi.2020.1596.
To the Editor The COVID-19 pandemic has been consistently on the rise across the globe. The recovered patients getting long-term sequelae, especially lung fibrosis and residual neurological deficits, is an area of concern. Another extremely important conundrum is the risk of re-infection. It has been recently documented from Hong Kong and puts an unpleasant question mark on long term immunity, sampling technique standardization, viral mutation and efficacy of herd immunity. There are definitions for COVID -19 infection and its severity, but unfortunately none for re-infection.
全球范围内，新冠疫情持续蔓延。康复患者出现长期后遗症，尤其是肺纤维化和残留神经功能缺损，这是一个令人担忧的领域。另一个极其重要的难题是再次感染的风险。最近香港有相关报道，这给长期免疫力、采样技术标准化、病毒突变和群体免疫效果都带来了令人不快的问号。对于新冠病毒感染及其严重程度有明确的定义，但遗憾的是，对于再次感染却没有定义。
